Picotamide (brand name Plactidil) is a platelet aggregation inhibitor. It works as a thromboxane synthase inhibitor and a thromboxane receptor inhibitor, the latter by modifying cellular responses to activation of the thromboxane receptor. Picotamide is licensed in Italy for the treatment of clinical arterial thrombosis and peripheral artery disease.

Spiramycins are macrolides produced by cultures of Streptomyces ambofaciens from the soil of northern France. The mixture of spiramycins have been successfully separated into three different components termed as Spiramycin I, II and III, which differ structurally in the acylation moieties on the C3 of the lactone. The SP I component contains a hydroxyl group at C3. The drug is effective against gram-positive aerobic pathogens, N. gonorrhoeae, and staphylococci. It is used to treat infections caused by bacteria and Toxoplasma gondii.

Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2. Rebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China, and India (where it is marketed under the trade name Rebagen). It is not approved by the Food and Drug Administration for use in the United States. Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa.

Potassium magnesium citrate has being proven to be an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Liquid potassium magnesium citrate has being studied in clinical trial for controlling Hypertension. Provision of alkali as potassium-magnesium citrate is an effective countermeasure for the increased risk of renal stone disease associated with immobilization. Despite an increase in urine calcium concentration, the relative saturation of calcium oxalate decreased due to citrate chelation of calcium and the concentration of undissociated uric acid decreased due to the significant increase in urine pH. Potassium magnesium citrate is a nutritional supplement that fights kidney stones in three different ways. The potassium provided by the supplement raises the pH of the urine, making it more alkaline, thus reducing the amount of calcium that the urine can dissolve. When there is less calcium in the urine, fewer calcium kidney stones can form. The magnesium in the supplement reduces the amount of calcium the kidneys pump out of the body and into the urine. And the citrate in the supplement keeps oxalates dissolved in the urine so they are flushed away before they can form kidney stones.

Seratrodast belongs to a class of medication called thromboxane A2/prostaglandin endoperoxide receptor antagonist. Seratrodast blocks the broncho-constrictor effects of certain chemicals (prostaglandins) in the body. Seratrodast also decreases the inflammation by antagonising the thromboxane A2 receptor. Adverse effects include gastrointestinal disturbances, drowsiness, headache, palpitations, and hepatitis. Seradair may interact with Ozagrel.

Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography (MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels. Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness) of blood. The extended acquisition time and increased relaxivity of gadofosveset allows for longer steady-state acquisition times, and potentially submillimeter voxels. Overlay of veins in steady-state MR angiography is less of a problem in multiplanar reformats with this level of resolution. This is particularly promising for MR evaluation of the peripheral vasculature. In the United States, gadofosveset is FDA-approved only for use in aortoiliac disease, with other uses being off-label. It currently does not have a role in hepatic imaging.

Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has anticoagulant and anti-inflammatory properties. Nafamostat is approved and marketed in Japan. It relieves symptoms such as pain due to inflammation of the spleen. It improves visceral disorders and bleeding tendency caused by blood clotting tendency in the vessels. It prevents coagulation in the blood circuit during hemodialysis. It is usually used to improve acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation phase of chronic pancreatitis, post-operative acute pancreatitis, acute pancreatitis after pancreatography, traumatic pancreatitis) and to prevent disseminated intravascular coagulation (DIC) and clotting of perfusing blood in extracorporeal blood circuit. Nafamostat mesilate significantly inhibits the release of platelet beta-thromboglobulin (beta TG) at 60 and 120 min. Nafamostat mesilate (NM) prevents any significant release of neutrophil elastase; at 120 min, plasma elastase-alpha 1-antitrypsin complex is 0.16 mg/mL in the NM group and 1.24 mg/mL in the control group. Nafamostat mesilate completely inhibits formation of complexes of C1 inhibitor with kallikrein and FXIIa.

Phosmet is a non-systemic, organophosphate insecticide used on both plants and animals. Phosmet is mainly used on apple trees for control of coddling moth, though it is used on a wide range of fruit crops, ornamentals and vines for the control of aphids, suckers, mites and fruit flies. Phosmet is a moderately potent cholinesterase inhibitor.

Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. It is considered safe and effective for the treatment of gastritis and gastric ulcer. It is used in Japan. Adverse reactions are: liver dysfunction, jaundice, rash, constipation, dry mouth, heartburn.

Octamylamine is an Antispasmodic. Trademark: Octinum D.